This is a working overview of deamidation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
In early July 2018, then Education Minister, Lisa Thompson, told Queen's Park reporters that starting in September 2018, Ontario schools would no longer be using the sex education curriculum in use since 2015, but would be reverting to the previous curriculum. One of the election campaign promises by the Ford government was to "scrap" the 2015 sex education curriculum. Premier Ford's government said that "it did not order the cancellation." By August 2019, the Ministry of Education, following "widespread consultations," made "only minor tweaks". The "health lesson plan being brought to schools in the fall" of 2019 "is similar to the one Ford crusaded against." On October 11, 2019, Minister Lecce reached a deal with CUPE school support workers, which has to be ratified by CUPE members and averted a pending strike. Premier Ford had said that he would cap "all public sector wage settlements at one per cent per year". The three-year agreement with CUPE was for a "one per cent wage increase annually for the duration of deal." A clause in the agreement clause in the agreement says that if "higher increases are negotiated by other education unions", their union will be able to increase to more than one percent. CUPE also had $58.3 million restored for the "hiring of educational assistants" with an additional $20 million for hiring "more custodians and clerical workers." As well, CUPE's sick leave provisions remained untouched.
=== Precursor to other peroxide compounds === Hydrogen peroxide is a weak acid, forming hydroperoxide or peroxide salts with many metals. It also converts metal oxides into the corresponding peroxides. For example, upon treatment with hydrogen peroxide, chromic acid (CrO3 and H2SO4) forms a blue peroxide CrO(O2)2.
Brown and white granulated sugar are 97% to nearly 100% carbohydrates, respectively, with less than 2% water, and no dietary fibre, protein or fat (table). Because brown sugar contains 5–10% molasses reintroduced during processing, its value to some consumers is a richer flavour than white sugar.
=== June === 7 June – The UK Health Security Agency issues a heat health alert for parts of England during the upcoming weekend, when temperatures are expected to reach 30 °C. Woking Borough Council imposes emergency spending restrictions on itself because of a £2bn debt. 8 June – The UK Health Security Agency upgrades the heat health warning for the upcoming warm weather to an amber alert. Henderson Hall in Newcastle is destroyed by a large fire. 9 June – The Independent Office for Police Conduct (IOPC) launches an investigation into the death of a 15-year-old boy whose e-scooter crashed into an ambulance in Salford the previous day, and shortly after he was followed by officers from Greater Manchester Police. Three people, including two students, are described as being in hospital following an assault at the privately run Blundell's School in Tiverton, Devon. A local teenager has been arrested. 10 June – A 16-year-old youth is charged with two counts of attempted murder and one of grievous bodily harm following the previous day's incident at Blundell's School. 11 June – Eight teenagers – six boys and two girls – are arrested following the fatal stabbing of a 16-year-old male youth at a house party in Bath, Somerset the previous evening. 13 June – Three people are killed in attacks across Nottingham City Centre. 21 June – A man is arrested after two people are stabbed at London's Central Middlesex Hospital. He is subsequently charged over the incident. 23 June – Junior doctors in England announce a five-day strike from 7am on 13 July, their longest so far.
In March 1916 (BR.23–BR.26), Robertson announced the results of a series of experiments that he and his assistant, Louis Adolph Ray, had conducted with the white mice — chosen as his "experimental animal" because of their "hardiness, rapid growth, smallness, and fecundity" (BR.23, p.366) — wherein the oral administration of tethelin, a "growth-controlling principle" (which they later described as "the ether-precipitable fraction of an alcoholic extract of the anterior lobe of the pituitary body"), produced precisely "the same effects on their growth" as those "which [had] accompan[ied] the [oral] administration of the whole tissue of the anterior lobe of the pituitary body" to his control group (BR.25, p.397). As Everitt (AE.2, p.63) notes — having distinguished (p.66) Robertson and Ray's "growth controlling principle" of the pituitary (BR.35) from Moon, et al.'s "growth stimulating principle" (HM.2) — it was not until the (1921) work of Herbert Evans and Joseph Long (HE.1; HE.2) that "[it was] conclusively proved that the pituitary contained a growth-stimulating hormone". Evans and Long also discovered that, whilst the oral administration of their "pituitary principle" had no effect, administration per medium of an intraperitoneal injection was effective: which led them to the conclusion that whatever the pituitary's 'active principle' might be, it was "digested in the alimentary canal".
Sources: en.wikipedia.org
At the beginning of sleep, a patient is in light sleep with no loss of tone in the throat muscles. Airflow is laminar and soundless. As the upper airway collapses, the obstruction becomes increasingly apparent with the initiation of noisy breathing as air turbulence increases, followed by gradually louder snoring as a Venturi effect forms through the ever-narrowing air passage. The patient's blood-oxygen saturation gradually falls until sleep noise stops, signifying total airway obstruction. This may last for several minutes. Eventually, the patient must at least partially awaken from deep sleep into light sleep, automatically regaining general muscle tone. This switch from deep to light to deep sleep can be recorded using ECT monitors. In light sleep, muscle tone is near normal, the airway spontaneously opens, normal noiseless breathing resumes, and blood oxygen saturation rises. Eventually, the patient reenters deep sleep, upper airway tone is lost, the patient enters the various levels of noisy breathing, and airway blockage returns. The cycle of muscle tone loss and restoration, coinciding with periods of deep and light sleep, repeats throughout the patient's sleep period. The number of apnoea and hypopnoea episodes during any given hour is counted and given a score. If a patient has an average of five or more episodes per hour, mild OSA may be confirmed. An average of 30 or more episodes per hour indicates severe OSA.
== Education and academic career == Bhushan began his education in his native India, completing his undergraduate and master's degrees from the University of Jodhpur. He received his Ph.D. in chemistry (working on structure elucidation of natural products isolated from certain desert plants) in 1978 at the University of Jodhpur. Bhushan joined as a lecturer at the University of Roorkee (now Indian Institute of Technology Roorkee, India) in 1979 and was later selected for the position of full professor of chemistry in 1996 and served there till retirement in 2018.
=== Francis Crick Medal and Lecture === The Francis Crick Medal and Lecture was established in 2003 following an endowment by his former colleague, Sydney Brenner, joint winner of the 2002 Nobel Prize in Physiology and Medicine. The lecture is delivered annually in any field of biological sciences, with preference given to the areas in which Francis Crick himself worked. Importantly, the lectureship is aimed at younger scientists, ideally under 40, or whose career progression corresponds to this age. As of 2019, Crick lectures have been delivered by Julie Ahringer, Dario Alessi, Ewan Birney, Simon Boulton, Jason Chin, Simon Fisher, Matthew Hurles, Gilean McVean, Duncan Odom, Geraint Rees, Sarah Teichmann, M. Madan Babu and Daniel Wolpert.
=== Setting === According to the game's introductory cutscene, the Gunmen act as a sort of military police force for humanity's inter-galactically expanding colonial empire at an unknown time period in the distant future. During a mission five years prior to the beginning of the game, the Gunmen were dispatched to a planet called Banzure Prime to investigate a communications breakdown with a research colony there, under the command of their leader, known simply as "The General". While investigating the colony, they come under attack by massive, worm-like organisms that form one part of a larger genus of creatures known as "Xenomes". The General, seeing his men have no chance by themselves, takes command of one of the Gunmen's dropships and begins performing bombing runs on the attacking Xenomes, destroying several before being captured in the jaws of one of the larger creatures. Meanwhile, the player character, Major Archer, rallies the remaining gunmen and orders them to retreat to the remaining ships and get off-world immediately, assuming that the general is already dead. The General, still alive as his fighter is dragged underground, pleads (apparently unheard) for rescue over the radio, but the Gunmen leave before having a chance to receive the message.
Sources: en.wikipedia.org
== Acceptable levels of consumption == The acceptable daily intake (ADI) value for food additives, including aspartame, is defined as the "amount of a food additive, expressed on a body weight basis, that can be ingested daily over a lifetime without appreciable health risk". The Joint FAO/WHO Expert Committee on Food Additives (JECFA) and the European Commission's Scientific Committee on Food (later becoming EFSA) have determined this value is 40 mg/kg of body weight per day for aspartame, while the FDA has set its ADI for aspartame at 50 mg/kg per day – an amount equated to consuming 75 packets of commercial aspartame sweetener per day to be within a safe upper limit. The primary source for exposure to aspartame in the US is diet soft drinks, though it can be consumed in other products, such as pharmaceutical preparations, fruit drinks, and chewing gum among others in smaller quantities. A 12-US-fluid-ounce (350 ml; 12 imp fl oz) can of diet soda contains 0.18 grams (0.0063 oz) of aspartame, and, for a 75-kilogram (165 lb) adult, it takes approximately 21 cans of diet soda daily to consume the 3.7 grams (0.13 oz) of aspartame that would surpass the FDA's 50 mg/kg of body weight ADI of aspartame from diet soda alone. Studies of aspartame consumption in the US, Europe, Australia and other countries have shown that even high levels of intake are well below the ADI for safe consumption.
Several captured Boers, including Lotter and Scheepers, who was captured when he fell ill with appendicitis, were executed by the British for treason or for capital crimes such as the murder of British prisoners or unarmed civilians. Some of the executions took place in public, to deter further disaffection. Fresh Boer forces under Jan Christiaan Smuts, joined by the surviving rebels under Kritzinger, made another attack on the Cape in September 1901. They suffered severe hardships and were hard pressed by British columns, but eventually rescued themselves by routing some of their pursuers at the Battle of Elands River and capturing their equipment. From then until the end of the war, Smuts increased his forces from among Cape rebels until they numbered 3,000. However, no general uprising took place, and the situation in the Cape remained stalemated. In January 1902, Boer leader Manie Maritz was implicated in the Leliefontein massacre in the far Northern Cape.
=== Ear barotrauma === Barotrauma can affect the external, middle, or inner ear. Middle ear barotrauma (MEBT) is the most common diving injury, being experienced by between 10% and 30% of divers and is due to insufficient equilibration of the middle ear. External ear barotrauma may occur if air is trapped in the external auditory canal. Diagnosis of middle and external ear barotrauma is relatively simple, as the damage is usually visible if severe enough to require intervention.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.